109 filings
Page 2 of 6
8-K
d4hzt3xj
24 Sep 21
Departure of Directors or Certain Officers
4:09pm
8-K
av0m991usc1ktmbj
12 Aug 21
Sio Gene Therapies Announces Corporate Updates and Fiscal First Quarter 2021 Financial Results
7:22am
8-K
lyaczxib
9 Jun 21
Sio Gene Therapies Announces Fiscal Year 2020 Year-End Financial Results and Expected Fiscal Year 2021 Key Milestones
7:02am
8-K
cka17p
13 May 21
Sio Gene Therapies Announces CSF Reductions in GM1 Ganglioside from Clinical Trial of AXO-AAV-GM1 Gene Therapy
7:01am
8-K
o3g7lnwg1jqti6ia51xj
5 Apr 21
Departure of Directors or Certain Officers
5:10pm
8-K
4krzct27md
15 Mar 21
Sio Gene Therapies Provides Update on Cash Position and Major Upcoming GM1 Gangliosidosis Program Milestones
7:02am
8-K
auy2nv4 myzu32dwemj
9 Feb 21
Results of Operations and Financial Condition
7:02am
8-K
myk9 h1mbxjlf
4 Feb 21
Sio Gene Therapies Announces Receipt of $11.6 Million from Closing of the Sale of Arvelle Therapeutics
7:02am
8-K
uiusu24lw2 annbgps
3 Feb 21
Regulation FD Disclosure
7:03am
8-K
p65ot79bgae
4 Jan 21
Sio Gene Therapies to sell Arvelle Stake as part of Angelini Pharma’s Acquisition of Arvelle Therapeutics
8:01am
8-K
anflp9eisj8
18 Dec 20
Entry into a Material Definitive Agreement
6:00am
8-K
ebx2fudxb2 zk8a8
15 Dec 20
Sio Gene Therapies Announces Positive Six-Month Follow-Up Data from Low-Dose Cohort of Phase 1/2 Trial of AXO-AAV-GM1 for GM1 Gangliosidosis
4:04pm
8-K
x1lgwfi33
13 Nov 20
Results of Operations and Financial Condition
7:03am
8-K
bgp 8l2amq3ko2
10 Nov 20
Axovant Gene Therapies Announces Name Change to Sio Gene Therapies
7:02am
8-K
qma4y5ljxxg4
9 Nov 20
Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 Gene Therapy in Tay-Sachs and Sandhoff Diseases
7:00am
8-K
aicc4k4
29 Oct 20
Regulation FD Disclosure
4:03pm
8-K
ww65e7qum57fhop43
13 Oct 20
Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM2 for Tay-Sachs and Sandhoff Disease
7:01am
8-K
d5vpcypq3bf
9 Oct 20
Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM1 for GM1 Gangliosidosis
7:00am
8-K
h3d8nca aqdo
8 Oct 20
Departure of Directors or Certain Officers
7:16am
8-K
ht4efusvz7optj 3vdym
6 Oct 20
Axovant Gene Therapies Announces Positive Six-month Follow-up Data from Second
7:14am